A conversation with COTA CEO Miruna Sasu about RWE, also save $600 by registering now for INVEST 2023.
UpcomingEvent & On-Demand Podcast
INVEST 2023 will unite innovative startups, active investors as well as forward-thinking healthcare providers, payers and life science companies. Join us for exclusive networking opportunities and engaging content that highlights the opportunities and challenges the industry faces as it continues to evolve.
In this episode of MedCity's Pivot Podcast, Miruna Sasu, CEO of RWE company COTA, explained that studies have shown meaningful percentage improvements in efficiency— from the low single digits to double digits — if RWE is used in drug development. And that translates into real savings. Sasu believes that innovative life science companies are experimenting with RWE in drug development and clinical trials. However, she worries that in the midst of the current economic belt-tightening, efforts to leverage novel methods and technologies, including RWE, will be the first casualty.
No comments